# Trajectory-Based Prognostic Modeling in Hepatocellular Carcinoma

> **NCT07204262** · — · COMPLETED · sponsor: **Xu Yong, MD** · enrollment: 379 (actual)

## Conditions studied

- Liver Cancer

## Interventions

- **COMBINATION_PRODUCT:** Molecular Targeted Therapy (TKI / anti-VEGF antibody) PD-(L)1 Inhibitor Immunotherapy Interventional Therapy (TACE / HAIC)

## Key facts

- **NCT ID:** NCT07204262
- **Lead sponsor:** Xu Yong, MD
- **Sponsor class:** OTHER
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2018-01-01
- **Primary completion:** 2024-11-01
- **Final completion:** 2024-11-01
- **Target enrollment:** 379 (ACTUAL)
- **Last updated:** 2025-10-02


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07204262

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07204262, "Trajectory-Based Prognostic Modeling in Hepatocellular Carcinoma". Retrieved via AI Analytics 2026-05-25 from https://api.ai-analytics.org/clinical/NCT07204262. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*